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Antibody titres in immunoglobulin preparations 
for intravenous use were tested against 24 dif­
ferent enterovirus serotypes and varied between
1 : 100 and 1 : 10,000 within a single batch. Dif­
ferences up to 8-fold were found for homolo­
gous titres between two different batches that 
were prepared 6 years apart. The lowest titre ob­
tained was 1 : 40. The observed differences 
within and between the two batches could not 
be explained by different incidence of serotypes 
of enteroviruses circulating at the time blood 
was collected. Differences in titres of up to 18- 
fold were observed when several strains of the 
same serotype were tested suggesting that in- 
tratypic variation influences antibody titres.
It is concluded that Immunoglobulin prepara­
tions contain antibodies against many enterovi­
ruses, but that titres can be low and cannot be 
predicted from the incidence of any particular 
serotype circulating in the community. Because 
of intratypic variation, selection of a batch for 
specific treatment should be based on results 
obtained with the patient's own isolate, and not 
with a reference strain. J. Med. Virol. 53:273-
276, 1997. © 1997 Wiley-Liss, Inc.
KEYWORDS: neutralizing antibody; enterovi­
ruses; intravenous im m uno­
globulins
INTRODUCTION
Enter o'viral infections are common, especially in neo­
nates and infants, and are usually asymptomatic or 
associated with nonspecific signs such as fever and flu­
like symptoms. However, such infections are occasion­
ally severe, or even fatal, causing myocarditis, hepati­
tis, meningitis, or meningoencephalitis. The host’s con­
stitution and the virulence of the circulating virus are 
main determinants of disease severity [Melnick, 1996], 
and antibodies are known to play a pivotal role in re­
solving infection. Thus, patients who suffer from hypo- 
or agammaglobulinaemia and who are at risk of
chronic meningoencephalitis can be given effective pro­
phylaxis with intravenous immunoglobulins (IVIG) 
[Galama, 1997; McKinney et al., 1987; Rotbart, 1995]. 
Once chronic meningoencephalitis becomes estab­
lished, high doses of immunoglobulin must be given by 
the IV route and sometimes intrathecally. Ideally, im­
munoglobulins with a high titre of specific antibody 
against the strain involved should be given, but the 
virus cannot always be cultured from cerebrospinal 
fluid [Galama, 1997; Rotbart, 1995].
Neonates are also at risk of severe enteroviral dis­
ease [Cherry, 1995; Galama, 1997; Modlin, 1986]. They 
have subtle impairments of their host defenses and 
rely partly on maternally derived antibody for protec­
tion [Lewis and Wilson, 1996]. Indeed, there is some 
evidence that these antibodies can ameliorate infec­
tions [Modlin et al., 1981; Naginton et al., 1983] and 
mother-to-child transmission in the absence of specific 
antibody is considered to be a risk factor for severe 
disease [Galama, 1997; Modlin, 1986]. This provides 
the rationale for treating neonates with severe entero- 
viral infection with IVIG. However, the efficacy of this 
form of treatment has yet to be established [Abzug et 
al., 1995a; Johnston and Overall, 1989; Naginton et al., 
1983], which is difficult because treatment has to be 
started promptly before any information becomes 
available on the specific antibody levels [Abzug et al.,
1995a;1995b].
Immunoglobulin is prepared from a pool of several 
thousand blood donations, as it is generally accepted 
that this will provide broad-spectrum coverage against 
the common nonpolio enteroviruses, of which 65 differ­
ent serotypes exist while minimising batch-to-batch 
variation. However, little is known about the specific 
antibody levels in these preparations. Therefore, we 
determined the amount of neutralizing antibody 
against 24 different serotypes of enterovirus in two
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batches of immunoglobulin that had been prepared 6 
years apart and compared the antibody titres with the 
incidence of the different enteroviral serotypes that 
predominated in the Netherlands at the time the blood 
had been donated.
MATERIALS AND METHODS 
V iruses
The nonpolio enteroviruses consist of 65 serotypes:
23 coxsackie A viruses (CAV), 6 coxsackie B viruses 
(CBV), 32 echoviruses (EV), and the enteroviruses 
(Ent), numbered 68-71 [Melnick, 1996], The 20 sero­
types that occurred in the Netherlands during 1979-
1994 with an incidence of >1% were selected, based on 
14,471 isolates, of which 10465 (72%) were serotyped. 
In addition, 4 serotypes were included that were found 
with an incidence of <1%, but had been reported as 
causing severe disease [Cherry, 1995; McKinney et aL, 
1987; Verboon-Maciolek et al., 1997]. Together, these
24 serotypes accounted for 90% of the isolates sero­
typed in the Netherlands during this period. Prototype 
strains of enteroviruses and some clinical isolates were 
obtained from the National Institute of Public Health 
and Environmental Protection (RIVM) in Bilthoven, 
the Netherlands and from our laboratory. Virus stocks 
were prepared by growing virus at low multiplicity of 
infection in buffalo green monkey (BGM) cells. Once 
the maximum cytopathic effect (CPE) was obtained, 
the entire culture was treated with chloroform 
[Kapsenberg, 1988], centrifuged at low speed and the 
supernates stored in small amounts at -80°C.
Virus T itration
Virus stocks were titrated using a microtitration 
method, involving 4-fold dilutions. Each dilution was 
tested in 8 wells of a 96-well plate containing BGM 
cells [van Kuppenveld et al., 1995], The tissue culture 
infective dose (TCID50) that resulted in a CPE in 50% 
of the cultures was calculated according to the method 
of Reed and Muench [1938].
Im m unoglobulin Preparations
Immunoglobulin preparations were kindly provided 
by the Central Laboratory of the Netherlands Red 
uross Blood Transfusion Service (CLB; Amsterdam, 
the Netherlands). Lot CLB-890628-675 had been col­
lected during 1986-1988, and lot CLB-950518-H61 
during 1992-1994. Each batch contained the pooled Ig 
fractions derived from 3,000-5,000 donor units. Ig 
batches were considered to be representative for the 
whole country, since blood had been collected at Na­
tional Blood Centres and by additional campaigns con­
ducted in those regions lacking a blood donation centre. 
The preparations were freeze-dried and stored at 4°C. 
Immediately before use, they were reconstituted using 
distilled water in accordance with the manufacturer’s 
instructions to a concentration of 6 g/dl.
A microneutralization assay was carried out in 96- 
well plates seeded with 104 BGM cells per well in 0.2 
ml of minimal essential medium (MEM), containing so­
dium bicarbonate, antibiotics and 2% fetal bovine se­
rum. The plates were incubated in a C02 incubator at 
37°C. Virus stocks were diluted to a concentration of 
2,000 TCID50/inl. Reconstituted IG was diluted twofold 
from 1 : 4 to 1 : 2,048, or higher if  needed in MEM 
containing HEPES buffer and antibiotics; 0.5 ml of Ig 
dilution was mixed with 0.5 ml of diluted virus suspen­
sion containing 1,000 TCID50. These mixtures were 
then incubated for 1 hr at 37°C and overnight at 4°C. 
Next day, 0.1 ml medium was removed from each well 
and replaced by 0.1 ml of the virus-Ig mixtures. Each 
dilution was tested in 8 wells. The final virus dose was 
checked by backtitration of 18 control samples without 
antibody and was estimated to be a mean 46 ± 10 
TCID60/well (±2 SD). Neutralization reactions were 
read after 3 and 5 days and 50% endpoints were calcu­
lated according to the method of Reed and Muench 
[1938], The precision of the neutralization assay was 
calculated for experiments using 6 different serotypes 
that were repeated on 7 different days; the mean dif­
ference in titre was found to be 1.69 ± 1.1 (±2 SD).
Epidem iology
The enteroviruses that had circulated in the commu­
nity during 1979™1994 were held in the registry of the 
Netherlands Working Group on Clinical Virology, 
which involves nearly all virus diagnostic laboratories 
in the Netherlands, reporting results on a monthly ba­
sis. The number of diagnostic laboratories increased 
from 8 in 1979 to 15 in 1991, and each has a regional 
function so that the whole country is covered. Most of 
the laboratories make use of the same virus isolation 
and typing procedures [Kapsenberg, 1988], although 
the sensitivity of their techniques may have differed. 
Furthermore, asymptomatic and mild infections would 
have remained undetected since these cases are seldom 
referred for viral diagnosis. Therefore, the data re­
ported provides only a rough estimate of the actual 
incidence of individual viral infections in the commu­
nity.
RESULTS
Titres ranging from 1 : 40 to 1 : 10,720 were found 
against the various serotypes (Table I) and differences 
of up to 8-fold were noted between the two batqhes. 
There was no obvious correspondence between the lev­
els of any particular antibody and the incidence of in­
fection with that serotype in the Netherlands during 
1979-1994. Comparison for two shorter periods of 5 
years, starting shortly before, and ending after blood 
had been donated again failed to reveal any relation­
ship between the titres and the incidence of the various 
viral infections current at the time. Several strains 
of serotypes CBV2, CBV3, E9, and E20 were tested 
to investigate a possible effect of intratypic varia-
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TABLE I. Virus Strains, Incidence, and Titres of
Neutralizing Antibody in IVIG
Serotype Strain %a CLB-1989° CLB-1995C
CAV 9 Bozek 3.0 1,450 2,690
CBV1 Tucson 2.0 890 1,620
CBV 2 Ohio-1 2.8 3,550 2,880
Pretorius 1,510 300
CBV 3 TVDee 4.3 340 2,690
Nancy 1,230 150
CBV4 Tilo 3.0 1,590 10,720
CBV 5 Dekking 3.5 1,740 260
EV 1 Farouk 1.1 210 480
EV 2b Cornelis 0.3 150 450
E V 3 Morrisey 2.0 280 690
EV 5 Noyce 1.9 650 720
EV 6 D’Amori 4.5 630 590
EV 7 Wallace 3.2 1,450 1,620
EV 9 Hill 2.4 1,450 1,020
Meyer 1,290 3,020
EV 11 Gregory 6.7 720 400
EV 14 Tow 2.4 200 230
EV 18 Metcalf 1.6 110 170
EV 19b Burke 0.2 790 5,750
EV 20b JV-1 0.9 340 350
MVM ’83 40 100
AZN ’95 130 140
EV 22 Harris 5.2 1,120 6,610
EV 24b DeCamp 0.3 50 100
EV 25 JV-4 2.5 720 1,910
EV 29 JV-10 1.5 100 100
EV 30 Bastianni 6.0 310 600
E n t 71 BRCR 1.3 500 1,660
“Percentages, based on 14,471 isolates obtained during 1979-1994 in 
th e  Netherlands.
bLow incidence, but reported to cause severe disease [Cherry, 1995; 
Verboon et al., 1997].
^Reciprocal values of titres, according to Reed and Muench.
tion which was indeed observed and resulted in differ­
ences of up to 18-fold in titres, particularly for CBV3 
(Table I).
DISCUSSION
IVIG is used frequently to protect patients with Ig 
deficiency against infections caused by common patho­
gens such as enteroviruses [van der Meer and Zeegers, 
1994]. Ig has also been used for the treatment of 
chronic meningoencephalitis caused by an enterovirus, 
but this treatment has little success. Even when given 
intrathecally, IVIG is rarely helpful, and the disease is 
fatal in most patients. Therefore, the emphasis is on 
prophylaxis, although there are no data in the litera­
ture to indicate how this can be achieved optimally. 
The dosage of IVIG for maintenance treatment has 
been increased during the past decades. The present 
recommendation in the Netherlands is to maintain IgG 
concentrations in serum of >5 g/L [van der Meer and 
Zegers, 1994], but an efficacy study with a much higher 
dose is in progress.
Ig preparations for intravenous use contain the 
pooled Ig fractions from at least 1,000 blood donations. 
Some manufacturers prepare even larger pools, con­
taining 5=20,000 units. It is conceivable that a large 
pool size will provide a more constant quality, with 
antibody specificities that reflect the incidences of com-
TABLE II. Incidences for Entroviruses During the Time
Periods of Blood Donation for IVIG
Period 1979-1994 1984-1988 1990-1994
Serotype
CAV 9 3.0* 2.3 4.2
CBV 1 2.0 1.4 2.7
CBV 2b 2.8b 3.1b 2.7b
CBV 3b 4.3b 4-,3b 6.3b
CBV 4b 3.0b 2.3b 3.4b
CBV 5 3.5b 4,3b 4.3b
EV 1 1.1 1.0 0.4
EV 2 0.3 0.4 0.2
EV 3 2.0 1.2 1.4
EV 5 1.9 0.2 0.9
EV 6 4.5 6.1 1.6
EV 7 3.2 3.6 3.2
EV 9 2.4 1.9 2.0
EV 11 6.7 6.3 6.1
EV 14 2.4 2.1 0.9
EV 18 1.6 1.5 2.4
EV 19b 0,2b 0.4b 0.1b
EV 20 0.9 0.6 1.2
EV 22b 5,2b 5.0b 7.4b
EV 24 0.4 0.3 0.1
EV 25 2.5 1.1 2.6
EV 29 1.5 1.0 3.1
EV 30 6.0 9.8 1.2
Ent 71 1.3 1.9 1.1
Number of isolates: 14,471 4,905 4,530
"Percentages of total numbers of enteroviruses, isolated in the Neth­
erlands during periods as indicated.
^Serotypes for which >4-fold difference in titres was observed between 
batch CLB-1989 and batch CLB-1995.
mon infections in the general population. To check this, 
we compared antibody titres of IVIG with the inci­
dences of the corresponding enteroviruses in the Neth­
erlands. Antibodies were detected against all 24 sero­
types tested, but the titres for different serotypes var­
ied up to 200-fold. These 24 serotypes comprised those 
that frequently circulate but included some also that 
were less frequent but that have been reported to cause 
severe disease. Unexpectedly, there was no relation­
ship between antibody titres and the incidence of sero­
types. This is illustrated by low antibody titres found 
for EV11 and EV30, which were frequently isolated 
throughout the observation period, and by an inverse 
relationship between the incidence of EV19 infection at 
different times and antibody titres (Tables I, II). This 
may be because the incidence data were based on clini­
cal isolates obtained from symptomatic infections that 
predominate in small children or because the serotypes 
that circulate among children differ from those among 
adults.
The differences between the two batches were only 
up to 8-fold, which is in the range reported by Dagan et 
al. [1983]. By contrast, Abzug et al. [1995a] found no 
variation in titres between 2 lots of IVIG derived from 
batches 10 times larger than those of the CLB. This 
suggests that a large pool size may reduce variability 
still further. On the other hand, these investigators 
provided no information on the interval between blood 
donations for the lots they tested. We also observed 
considerable variation in titres when several strains of
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the same serotype were tested, as did Abzug et al. 
[1995aL Thus, the large pool size does not appear to 
compensate for intratypic variations, which might also 
explain why we failed to find any relationship between 
epidemiology and antibody titres, since prototype 
strains were employed, and only a few strains that had 
recently been isolated from patients.
Virus neutralization is a complex event in which dif­
ferent mechanisms are involved, such as aggregation of 
virus particles through antibody cross-linking, block­
ing of virus-receptor interaction, inhibition of cell pen­
etration, or inhibition of uncoating [Mosser et al,, 
1989], Furthermore, it was recently shown that varia­
tion exists between individual virus isolates within the 
same serotype of coxsackie B virus in the capacity to 
bind to different cell surface receptors [Bergelson et al., 
1997]. Studies such as ours cannot test for all possible 
mechanisms of intratypic variation and will conse­
quently have limitations. Hence, it remains the ideal to 
test IVIG preparations for antibody using the patient’s 
own isolate despite the obvious difficulties involved. 
Nevertheless, our study has shown that antibody was 
at least present against all 24 serotypes employed. 
Some titres were low, but it is not known whether this 
might reduce therapeutic efficacy, nor does it give any 
indication of the titres that might be attained in a re­
cipient. This aspect of immunoglobulin treatment for 
enterovirus infections has received little attention so 
far and will be the subject of a future study in patients 
suffering from agammaglobulinemia.
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